Stocks lower, oil surges, Bristol Myers-Mirati, UAW strikes, Disney
The deadliest attacks on Israel in at least five decades has sent oil prices surging and puts global markets on edge heading into a key week on Wall Street.Iran's links to Hamas and Hezbollah, the groups responsible for the deadliest attacks on Israel in decades, has sent global oil prices surging over concerns of a region-wide conflict.Bristol Myers will pay up to $5.
8 billion for cancer treatment specialists Mirati Therapeutics in the last oncology deal in the fast-moving pharma sector.The United Autoworkers Union, which is entering its fourth week of strike action against the Big 3 automakers, rejected a tentative pay deal with Volvo-owned Mack Trucks late Sunday.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Mirati Stock Falls as Bristol Myers to Buy Oncology Developer for Up to $5.8 BillionThe acquisition will help boost revenue by offsetting upcoming competition from generics for Bristol Myers Squibb’s best-selling products.
Lire la suite »
Bristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reportsBristol-Myers Squibb shells out $5.8B for Mirati: 5 big deal reports
Lire la suite »
Bristol-Myers Squibb to acquire Mirati in $5.8 billion dealBristol-Myers Squibb (BMY.N) on Sunday said it will acquire Mirati Therapeutics (MRTX.O) in a transaction that values the cancer drugmaker at up to $5.8 billion.
Lire la suite »
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion dealBristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
Lire la suite »
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 BillionDeal expands pharmaceutical company’s portfolio of cancer drugs
Lire la suite »
Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionMirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its...
Lire la suite »